Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 30, 2018 07:30 ET | Source: Zai Lab Limited

Zai Lab Announces Financial Results and Corporate Progress for the Six Months ended June 30, 2018

SHANGHAI, China, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ:ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced financial...
August 28, 2018 07:30 ET | Source: Zai Lab Limited

Zai Lab Doses First Patient in Phase III Trial of ZL-2306 (niraparib) in Patients with Small-Cell Lung Cancer in China

First study of niraparib for this indication worldwide; a significant medical need in China SHANGHAI, China, Aug. 28, 2018 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a Shanghai-based...
August 24, 2018 08:00 ET | Source: Zai Lab Limited

Zai Lab Elects to Discontinue Development of ZL-3101 (Fugan) for Atopic Dermatitis

SHANGHAI, China, Aug. 24, 2018 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced the decision to discontinue the development...
August 22, 2018 08:00 ET | Source: Zai Lab Limited

Zai Lab Announces Presentations at the 21st Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) and the IASLC 19th World Conference on Lung Cancer (WCLC)

SHANGHAI, China, Aug. 22, 2018 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced that two studies will be presented at the...
August 20, 2018 07:30 ET | Source: Zai Lab Limited

Zai Lab’s ZL-2306 (niraparib) Completes Pharmacokinetics (PK) Study in Chinese Ovarian Cancer Patients Showing Comparable Profile to non-Chinese Patients

Niraparib made in China shows comparable PK profile to Tesaro’s product SHANGHAI, China, Aug. 20, 2018 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB), a Shanghai-based innovative...
August 14, 2018 07:30 ET | Source: Zai Lab Limited

Zai Lab Appoints Professor Kai-Xian Chen, Ph.D., to its Board of Directors

SHANGHAI, China, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced that Professor Kai-Xian Chen, Ph.D.,...
June 29, 2018 08:00 ET | Source: Zai Lab Limited

Zai Lab Announces Dosing of First Patient in Phase 3 China Registration Trial of ZL-2306 (niraparib) for First-Line Maintenance Therapy in Platinum Responsive Ovarian Cancer

SHANGHAI, June 29, 2018 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced dosing of the first patient in the Company’s Phase 3...
June 05, 2018 07:30 ET | Source: Zai Lab Limited

Zai Lab Expands Commercial Leadership Team, Appoints William Liang as Chief Commercial Officer

SHANGHAI, China, June 05, 2018 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced that William Liang has been appointed Chief...
May 30, 2018 07:30 ET | Source: Zai Lab Limited

Zai Lab and Crescendo Biologics Enter Exclusive Worldwide License Agreement for Innovative Protein Therapeutics for Inflammatory Indications

Candidate to expand Zai Lab’s early-stage R&D programs, with an anticipated IND Filing for clinical studies in psoriasis in 2019 SHANGHAI, China and CAMBRIDGE, United Kingdom, May 30, 2018 ...
May 29, 2018 16:01 ET | Source: Zai Lab Limited

Zai Lab Announces Presentations at June Investor Conferences

SHANGHAI, China, May 29, 2018 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced its participation in two upcoming investor...